Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats

被引:63
作者
Rumi, G [1 ]
Tsubouchi, R
Okayama, M
Kato, S
Mózsik, G
Takeuchi, K
机构
[1] Kyoto Pharmacol Univ, Dept Pharmacol & Expt Therapeut, Kyoto 6078414, Japan
[2] Univ Pecs, Fac Med, Dept Med 1, Pecs, Hungary
关键词
lactulose; prebiotics; experimental colitis; prophylactic effect; rat;
D O I
10.1023/B:DDAS.0000042248.48819.ad
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Promising results have recently been obtained with pre- and probiotic therapy in ulcerative colitis (UC). The prebiotic potential of lactulose is well established, but it has not yet been investigated in experimental colitis models. The purpose of the study was to examine the effect of lactulose on an UC model induced by 3% dextran sulfate sodium (DSS) solution added to drinking water for 7 days in male Wistar rats. Lactulose ( 300 - 1000 mg/ kg) or 5-aminosalicylic acid (5-ASA; 150 mg/kg) was administered orally twice daily for 6 days. Colonic ulceration area, colon length, body weight changes, diarrhea/bloody feces, colonic mucosal myeloperoxidase activity (MPO), thiobarbituric acid reactive substances (TBARS), and histology were examined. Treatment of animals with DSS for 7 days resulted in severe colonic lesions accompanied by diarrhea, bloody feces, a decrese in body weight, shortening of the colon length, and an increase in MPO activity as well as TBARS, compared to normal rats. Lactulose treatment ameliorated DSS-induced colitis in a dose-dependent manner, and at 1000 mg/ kg all of the parameters examined, except TBARS, were shown to improve significantly as compared to controls. Daily administration of 5-ASA also significantly reduced the severity of colonic lesions following DSS treatment. These results demonstrated the protectiv effect of lactulose in this rat colitis model and suggested that the background of this lactulose effect may be due to alterations of colonic microflora.
引用
收藏
页码:1466 / 1472
页数:7
相关论文
共 35 条
[1]  
Axelsson L., 1989, MICROB ECOL HEALTH D, V2, P131, DOI [DOI 10.3109/08910608909140210, 10.3109/08910608909140210]
[2]  
Bezkorovainy A, 2001, AM J CLIN NUTR, V73, p399S, DOI 10.1093/ajcn/73.2.399s
[3]   Treatment of ulcerative colitis using fecal bacteriotherapy [J].
Borody, TJ ;
Warren, EF ;
Leis, S ;
Surace, R ;
Ashman, O .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 37 (01) :42-47
[4]   EXPERIMENTAL-MODELS OF INFLAMMATORY BOWEL-DISEASE [J].
ELSON, CO ;
SARTOR, RB ;
TENNYSON, GS ;
RIDDELL, RH .
GASTROENTEROLOGY, 1995, 109 (04) :1344-1367
[5]   THE EFFECT OF EXOGENOUS ADMINISTRATION OF LACTOBACILLUS-REUTERI R2LC AND OAT FIBER ON ACETIC ACID-INDUCED COLITIS IN THE RAT [J].
FABIA, R ;
ARRAJAB, A ;
JOHANSSON, ML ;
WILLEN, R ;
ANDERSSON, R ;
MOLIN, G ;
BENGMARK, S .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (02) :155-162
[6]   Ulcerative colitis [J].
Farrell, RJ ;
Peppercorn, MA .
LANCET, 2002, 359 (9303) :331-340
[7]   Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium [J].
Fujiwara, M ;
Kaneko, T ;
Iwana, H ;
Taketomo, N ;
Tsunoo, H ;
Kanno, J ;
Ohkusa, T ;
Okayasu, I .
DIGESTION, 2003, 67 (1-2) :90-95
[8]   Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Helwig, U ;
Venturi, A ;
Lammers, KM ;
Brigidi, P ;
Vitali, B ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2003, 124 (05) :1202-1209
[9]  
GRISHAM MB, 1988, DIG DIS SCI S, V33, P6
[10]   Saccharomyces boulardii in maintenance treatment of Crohn's disease [J].
Guslandi, M ;
Mezzi, G ;
Sorghi, M ;
Testoni, PA .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (07) :1462-1464